

Triesence[®]

(triamcinolone acetonide
injectable suspension)

40 mg/mL



00085-0543-01 Sterile 1 mL 40 mg/mL
Triesence
triamcinolone acetonide injectable suspension
40 mg/mL
Alcon
Alcon Laboratories
Fort Worth, TX 76101
Store at 4°-25°C
(39°-77°F)
Do not freeze.
Single Use



TRIESENCE

(triamcinolone acetonide
injectable suspension)
40 mg/mL



Ophthalmic by design.™

Designed and FDA approved for intraocular use

Indications: treatment of uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids, sympathetic ophthalmia, and temporal arteritis. TRIESENCE® Suspension is also indicated for visualization during vitrectomy.

Preservative Free

Does not contain benzyl alcohol.

Terminally Sterilized

With terminal sterilization the probability that a unit is non-sterile is one in a million. Other injectable triamcinolone acetonide products that are aseptically processed have a one in a thousand probability of a non-sterile unit occurring.

Sterile Vial Exterior

Convenient for OR use.

TRIESENCE® Suspension is contraindicated in patients with systemic fungal infections and those with hypersensitivity to triamcinolone or any component of this product. Ophthalmic effects may include cataracts, infections, and glaucoma.

Package insert information on next page.
Currently available only in the U.S.

In the U.S. to order call 1-800-862-5266 or fax 1-800-241-0677.

TRIESENCE® Triamcinolone Acetonide

0065054301 | 1 mL | 1 each (LTX)

RETINA PHARMACEUTICALS

Ophthalmic by design.™



HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL safely and effectively. See full prescribing information for TRIESENCE® suspension. TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL Initial U.S. Approval: 1957

INDICATIONS AND USAGE

TRIESENCE® suspension is a synthetic corticosteroid indicated for:

- Treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. (1.1)
- Visualization during vitrectomy. (1.2)

DOSAGE AND ADMINISTRATION

- Initial recommended dose for all indications except visualization: 4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment. (2.1)
- Recommended dose for visualization: 1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally. (2.2)

DOSAGE FORMS AND STRENGTHS

Single use 1 mL vial containing 40 mg/mL of triamcinolone acetonide suspension. (3)

CONTRAINDICATIONS

- Patients with systemic fungal infections. (4)
- Hypersensitivity to triamcinolone or any component of this product. (4)

WARNINGS AND PRECAUTIONS

- TRIESENCE® suspension should not be administered intravenously. (5.1)
- Ophthalmic effects: May include cataracts, infections, and glaucoma. Monitor intraocular pressure. (5.1)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and hyperglycemia: Monitor patients for these conditions and taper doses gradually. (5.2)
- Infections: Increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection. (5.3)

- Elevated blood pressure, salt and water retention, and hypokalemia: Monitor blood pressure and sodium, potassium serum levels. (5.4)
- GI perforation: Increased risk in patients with certain GI disorders. (5.5)
- Behavioral and mood disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. (5.6)
- Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy. (5.7)
- Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids. (5.8)
- Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy. (5.9)
- Use in pregnancy: Fetal harm can occur with first trimester use. (5.10)
- Weight gain: May cause increased appetite. (5.11)

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Anticoagulant agents: May enhance or diminish anticoagulant effects. Monitor coagulation indices. (7)
- Antidiabetic agents: May increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required. (7)
- CYP 3A4 inducers and inhibitors: May respectively increase or decrease clearance of corticosteroids necessitating dose adjustment. (7)
- NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (7)

Full prescribing information available at:

http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022223,0220481bl.pdf

Revised: December 2010

To Order: call 800-TO-ALCON (1-800-862-5266) or fax the order to 1-800-241-0677
NDC # 0065-0543-01

Reimbursement Questions: call Alcon Reimbursement Services
at (866) 457-0277 or email ARS@alconlabs.com



*Designed and FDA approved for
intraocular use*

